## Abstract A specific allele of the NACP‐Rep1 polymorphism within the α‐synuclein promoter was found to be associated both with Parkinson's disease and essential tremor. We repeated the association study on a large series of Italian patients with essential tremor using a panel of polymorphisms wit
Genetic variants of α-synuclein are not associated with essential tremor
✍ Scribed by Owen A. Ross; Karen N. Conneely; Tao Wang; Carles Vilarino-Guell; Alexandra I. Soto-Ortolaza; Alex Rajput; Zbigniew K. Wszolek; Ryan J. Uitti; Elan D. Louis; Lorraine N. Clark; Matthew J. Farrer; Claudia M. Testa
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 264 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background:
Given the overlap between Parkinson's disease and essential tremor, we examined genetic variants in α‐synuclein (SNCA) as risk determinants for essential tremor.
Methods:
Samples from 661 essential tremor subjects and 1316 control subjects from 4 participating North American sites were included in this study. Parkinson's disease samples (n = 427) were compared against controls. Twenty variants were selected for association analysis within the SNCA locus. Individual logistic regression analyses against essential tremor diagnosis were run for each variant and then combined using meta‐analysis.
Results:
Our results do not show a significant association between variants in the SNCA locus and risk of essential tremor, whereas the established association of SNCA variants with Parkinson's disease risk was observed.
Conclusions:
Whereas genetic factors are likely to play a large role in essential tremor pathogenesis, our results do not support a role for common SNCA genetic variants in risk for essential tremor. © 2011 Movement Disorder Society
📜 SIMILAR VOLUMES
The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions